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Abstract Degeneration of motor neurons contributes to
senescence-associated loss of muscle function and underlies
human neurodegenerative conditions such as amyotrophic
lateral sclerosis and spinal muscular atrophy. The identifi-
cation of genetic factors contributing to motor neuron
vulnerability and degenerative phenotypes in vivo are
therefore important for our understanding of the neuro-
muscular system in health and disease. Here, we analyzed
neurodegenerative abnormalities in the spinal cord of
progeroid Ercc1D/- mice that are impaired in several DNA
repair systems, i.e. nucleotide excision repair, interstrand
crosslink repair, and double strand break repair. Ercc1D/-
mice develop age-dependent motor abnormalities, and have
a shortened life span of 6–7 months. Pathologically,
Ercc1D/- mice develop widespread astrocytosis and
microgliosis, and motor neuron loss and denervation of
skeletal muscle fibers. Degenerating motor neurons in many
occasions expressed genotoxic-responsive transcription
factors p53 or ATF3, and in addition, displayed a range of
Golgi apparatus abnormalities. Furthermore, Ercc1D/-
motor neurons developed perikaryal and axonal intermedi-
ate filament abnormalities reminiscent of cytoskeletal
pathology observed in aging spinal cord. Our findings sup-
port the notion that accumulation of DNA damage and
genotoxic stress may contribute to neuronal aging and motor
neuron vulnerability in human neuromuscular disorders.
Introduction
Functional decline and loss of motor neurons are key
pathological hallmarks of many human neuromuscular
diseases, including motor neuron diseases such as amyo-
trophic lateral sclerosis (ALS) and spinal muscular atrophy
[40, 42, 61]. Degeneration of motor neurons also contrib-
utes to age-associated loss of muscle function causing
slowing of movement, decline in strength and, eventually,
disability [18, 21, 32]. Genotoxic stress resulting from
cumulative damage to DNA is regarded as a dominant
mechanism underlying aging, and several lines of evidence
indicate that it contributes to aging processes in neurons
[26, 36, 52]. DNA is subject to spontaneous hydrolytic
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decay as well as continuous modification from both
endogenous reactive chemicals, such as reactive oxygen
species and malondialdehyde, and exogenous environ-
mental factors [3, 66]. Several forms of DNA damage, such
as strand breaks, base modifications, and cross-links (par-
ticularly protein–DNA) have been reported to accumulate
with age in a variety of tissues [3, 11, 19, 36, 37]. Being
post-mitotic, irreplaceable cells, neurons may accumulate
DNA lesions throughout life eventually causing functional
deterioration and cell death by interfering with transcrip-
tion [8, 12, 35, 51, 54].
The vulnerability of neurons to DNA lesions and the
importance of DNA repair pathways for neuronal mainte-
nance and survival are highlighted by a number of DNA
repair deficiency disorders that are characterized by neu-
rological deficits and neurodegenerative changes, in some
instances resembling accelerated aging of the nervous
system [7, 8, 37, 52]. DNA repair disorders with neuro-
degenerative changes include a variety of syndromes
associated with single strand break (SSB) and double
strand break (DSB) repair deficiency [37, 52], as well as
disorders resulting from defects in the nucleotide excision
repair (NER) pathway that removes helix-distorting and
transcription blocking lesions [30, 50]. Neuropathological
data have indicated that different brain regions and neu-
ronal types display differential susceptibility towards
specific DNA repair defects, and that the cerebellum is
particularly affected in many DNA repair deficiency syn-
dromes [8, 30, 37, 50, 52]. However, for most DNA repair
disorders the spatiotemporal distribution of degenerative
changes throughout the brain and spinal cord remains to be
systematically examined, and the role of DNA damage and
repair in maintenance and aging of motor neurons has yet
to be investigated.
Here, we have investigated the consequences of a failure
to repair DNA damage in motor neurons from DNA repair-
deficient Ercc1D/- mice. These mice lack one allele of the
excision repair cross-complementing group 1 (ERCC1)
gene, whereas the protein derived from the other allele
shows reduced activity, due to a seven amino-acid carboxy-
terminal truncation [65]. ERCC1 in complex with XPF acts
as a nuclease in the NER pathway [27], but in addition, it is
involved in interstrand crosslink and DSB repair [1, 9, 10,
49, 70]. Previous studies with ERCC1- and XPF-deficient
patients [2, 29, 49, 55] as well as Ercc1-/- and XPF-/-
mice [33, 38, 49, 59, 65] have indicated that loss of
ERCC1/XPF nuclease function causes a progeroid degen-
erative phenotype in several organ systems and juvenile
death. Ercc1D/- and Ercc1D/D mice show prolonged life
span and an attenuated degenerative phenotype compared
to Ercc1-/- mice, which can be explained by the low
level of residual ERCC1/XPF activity [17, 65]. Our data
show that Ercc1D/- mice develop age-dependent motor
abnormalities, disruption of neuromuscular connectivity at
the neuromuscular junction, and degeneration of motor
neurons. The data support the hypothesis that accumulation
of DNA damage and genotoxic stress significantly influ-
ences neuronal aging processes and may contribute to
motor neuron vulnerability in human neuromuscular
disorders.
Methods
Mice
Experiments were performed in accordance with the
‘‘Principles of laboratory animal care’’ (NIH publication
no. 86-23) and the guidelines approved by the Erasmus
University animal care committee. The generation of
Ercc1- and Ercc1D alleles has been previously described
[65]. Ercc1D/- mice were obtained by crossing Ercc1-/?
with Ercc1D/? mice of C57Bl6J and FVB backgrounds to
yield Ercc1D/- with C57Bl6J/FVB hybrid background
[17]. Wild-type, Ercc1D/?, and Ercc1-/? littermates were
used as controls. Mice were housed in individual ventilated
cages with ad libitum access to standard mouse food (CRM
pellets, SDS BP Nutrition Ltd; gross energy content
18.36 kJ/g dry mass, digestible energy 13.4 kJ/g) and
water. Ercc1D/- mice received liquefied food when they
were not able to reach the food due to movement disabil-
ities. The mice were weighed and visually inspected
weekly, and were scored for gross morphological and
motor abnormalities including the onset of kyphosis,
abnormalities in hind limb extension when lifted by the
tail, and balance and locomotion deficits. Motor perfor-
mance was further determined using a grip strength test and
accelerating Rotarod as described [28, 63].
Antibodies
Primary antibodies (supplier; dilutions) used in this study
were as follows: rabbit anti-ATF3 (Santa Cruz; 1:1,000);
rabbit anti-calbindin (Swant; 1:10,000); rabbit anti-cleaved
caspase 3 (Asp175; Cell Signaling Technology; 1:500);
rabbit anti-calreticulin (Affinity BioReagents; 1:5,000);
rabbit anti-CGRP (Calbiochem; 1:10,000); goat anti-ChAT
(Millipore; 1:500); rat anti-CR3 receptor (clone 5C6;
Serotec; 1:500); rabbit anti-FUS (A300-302A RP, Bethyl
Laboratories; 1:2,000); rabbit anti-GFAP (DAKO; 1:10,000);
mouse anti-GFAP (Sigma; 1:10,000); mouse anti-GM130
(Transduction Laboratories; 1:100); rat anti-Mac2 (Cedar-
lane; 1:2,000); mouse anti-NeuN (Millipore; 1:1,000);
chicken anti-neurofilament-M (Millipore; 1:2,000); rabbit
anti-neurofilament160 (Millipore; 1:250); mouse anti-
hyperphosphorylated neurofilament (SMI31, Sternberger
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Monoclonals; 1:20,000); mouse anti-non-phosphorylated
neurofilament (SMI32, Sternberger Monoclonals; 1:4,000);
rabbit anti-p53 (Leica; 1:1,000); rabbit anti-peripherin
(Millipore; 1:1,000); rabbit anti-SCG10 (gift from Dr. A.
Sobel; 1:4,000); rabbit anti-TDP43 (Proteintech; 1: 1,000);
rabbit anti-ubiquitin (Dako; 1:2,000); rabbit anti-VAPB
(#1006-00 [57]; 1:1,000).
For avidin–biotin–peroxidase immunocytochemistry,
biotinylated secondary antibodies from Vector Laborato-
ries diluted 1:200 were used. FITC-, Cy3-, and Cy5-
conjugated secondary antibodies raised in donkey (Jackson
Immunoresearch, USA) diluted at 1:200 were used for
immunofluorescence. Cy3-conjugated donkey anti-rabbit
Fab fragment (Jackson Immunoresearch) was used in
double-labeling experiments with two rabbit primary
antibodies.
Histological procedures
Mice were anaesthetized with pentobarbital and perfused
transcardially with 4% paraformaldehyde; lumbar and
cervical spinal cord were dissected out, post-fixed for 2 h
in ice-cold 4% paraformaldehyde, cryoprotected, embed-
ded in 10% gelatine blocks, rapidly frozen, and sectioned at
40 lm using a freezing microtome or stored at -80C until
use [64]. Frozen sections were processed free floating for
immunofluorescence or avidin–biotin–immunoperoxidase
complex method (ABC, Vector Laboratories, USA) with
diaminobenzidine (0.05%) as the chromogen as described
previously [64]. In addition, a selected number of frozen
gelatin sections was collected in 4% paraformaldehyde,
and processed with a modified Gallyas silver impregnation
procedure of Nadler and Evenson [43] that selectively
labels degenerating neurons and their processes. For dou-
ble-labeling immunofluorescence with two rabbit
antibodies Cy3-conjugated donkey anti-rabbit Fab frag-
ments was used to label and sterically cover the first
antibody, as described by the manufacturer (Jackson
Immunoresearch). Sections were then incubated with the
second antibody that was labeled consecutively with FITC-
conjugated donkey anti-rabbit.
Alternatively, brain and spinal cord specimens were
paraffin-embedded, sectioned at 4 lm, and mounted on
Superfrost slides. For immunohistochemistry, paraffin
sections were deparaffinized, rehydrated in decreasing
concentrations of ethanol, treated with 10 mM sodium
citrate buffer, pH 6, in the microwave for antigen retrieval,
and further processed using the ABC method. A series of
paraffin sections were employed for TdT-mediated dUTP
Nick-End Labeling (TUNEL) assay using a commercial kit
(Apoptag Plus Peroxidase in situ apoptosis detection kit,
Millipore). Sections were deparaffinized and incubated as
described by the manufacturer.
Immunoperoxidase-stained sections were analyzed and
photographed using a Leica DM-RB microscope and a
Leica DC300 digital camera. Sections stained for immu-
nofluorescence were analyzed with a Zeiss LSM 510
confocal laser scanning microscope. Quantitative analyses
of motor neurons were performed on serial lumbar 4 (L4)
sections immunoperoxidase stained for ChAT or CGRP as
described previously [28]. Parallel series were used for
counting ATF3- and p53-labeled cells.
Neuromuscular junction analysis
Neuromuscular junctions were analyzed in deep lumbrical
muscles stained for neurofilament 160 and a-bungarotoxin
(5 lg/ml for 30 min, Molecular Probes), as described
previously [41]. Muscles were whole-mounted in Mowoil
(Calbiochem) on glass slides and cover-slipped for sub-
sequent imaging using a Nikon IX71 epi-fluorescence
microscope equipped with a 409 oil immersion objective
(NA 0.8) or a BioRad Radiance 2000 Laser Scanning
confocal microscope. All analyses were undertaken by an
observer blind to the genotype of the specimen. Randomly
selected endplates (minimum of 100 per muscle) were
categorized as either fully innervated (e.g. ‘normal’: neu-
rofilament staining from a single axon entirely overlies
endplate), partially innervated, denervated (no neurofila-
ment overlies endplate), or poly-innervated (more than 1
axon converging on individual endplates).
Statistical analyses
Statistical analyses were performed using GraphPad Prism
Software (San Diego, CA, USA). Means from different
ages and mouse groups were compared using Student’s t
test, Kruskal–Wallis test with Dunn’s post-hoc test or one-
way ANOVA with Tukey’s post-hoc test.
Results
Ercc1D/- mice show reduced life span and develop
progressive motor abnormalities
Ercc1-/- and Ercc1D/D mice in pure C57Bl/6 or FVB
backgrounds are born at a frequency below Mendelian
expectation [65]. Therefore, in this study we have used
Ercc1D/- mice in a C57Bl6J/FVB hybrid background,
generated by crossing Ercc1-/? and Ercc1D/? mice of pure
C57Bl6J and FVB backgrounds, respectively, which were
born at a predicted Mendelian frequency. Ercc1-/? and
Ercc1D/? do not differ from wild-type mice and show
normal aging [17, 65], instead Ercc1D/- mice were
noticeably smaller and showed reduced body weight
Acta Neuropathol (2010) 120:461–475 463
123
compared to wild-type littermates (Fig. 1a, c). The mice
reached a maximal weight of 10–15 g at 6–8 weeks of age,
before gradually losing weight during subsequent aging
(Fig. 1c). From 3 to 8 weeks of age Ercc1D/- mice started
to show clasping of the hind-limbs when lifted by their
tails. Subsequently, Ercc1D/- mice developed fine tremors
and kyphosis, and from 16 to 24 weeks they showed severe
locomotor deficits and reduced ability to maintain balance
(Fig. 1a, b). Grip strength and accelerating rotarod analyses
showed reduced motor performance in 16 weeks compared
to 8-week-old Ercc1D/- mice (Fig. 1d, e). From 20 to
24 weeks Ercc1D/- mice had problems with feeding
themselves and became moribund. From this stage life span
could be extended by 2–6 weeks by giving liquefied food,
yielding a maximum life span of 24–30 weeks (Fig. 1b).
Ercc1D/- mice show age-related increase in astrocytosis
and microgliosis
Pathologically, Ercc1D/- mice develop mild histological
abnormalities in several tissues, in particular liver and kid-
ney, consistent with previous reported findings in Ercc1D/D
and Ercc1-/- mice [38, 49, 55, 65]. From a neuronal per-
spective, the brains and spinal cords of Ercc1D/- mice were
smaller than those from wild-type mice proportional to their
reduced size (Supplementary Fig. 1a, b). The gross histo-
logical organization analyzed using thionine-stained
sections appeared normal (data not shown). Similarly, the
distributions of markers that identify anatomically distinct
subpopulations of neurons such as calbindin (Supplementary
Fig. 1c, d) or non-phosphorylated neurofilament (Smi32-
Fig. 1 Progressive motor abnormalities and reduced life span in
Ercc1D/- mice. a Photograph of 4- and 16-week-old Ercc1D/- mice,
illustrating kyphosis and abnormal limb position in the 16-week-old
mouse. b Survival plot of Ercc1D/- mice (n = 10) and wild-type (wt)
littermates (n = 10) showing reduced life span of Ercc1D/- mice.
c X–Y plot of body weight (mean ± SE, n = 5 per group) of Ercc1D/-
and wt mice used for survival analysis. d Bar graph (mean ± SE,
n = 8 per group) of grip strength of Ercc1D/- and wt mice determined
by placing mice with four limbs on a grid attached to a force gauge
and steadily pulling the mice by their tails. Grip strength is defined as
the maximum strength produced by the mouse before releasing the
grid. *P \ 0.01 compared to wild-types; #P \ 0.01 compared to
8-week-old Ercc1D/- mice (two-tailed Student’s t test). e Average
time spent on an accelerating rotarod of 8- and 16-week-old Ercc1D/-
mice and wt littermates. Mice were given two trials of maximally
5 min per day with a 45–60-min inter-trial interval for five
consecutive days. Values represent mean ± SE (n = 8 per group)
464 Acta Neuropathol (2010) 120:461–475
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epitope, data not shown) were indistinguishable in Ercc1D/-
and wild-type mice.
To determine whether Ercc1D/- mice develop neuro-
degenerative changes, we first examined glial markers that
are known to be up-regulated in response to neuronal injury
and degeneration. In 4-week-old Ercc1D/- mice, glial
acidic filament protein (GFAP)-immunohistochemistry
revealed small areas of increased GFAP staining through-
out the brain (Supplementary Fig. 1f) and spinal cord as
shown in Fig. 2b. The amount of GFAP staining increased
with subsequent aging resulting in high levels of GFAP
staining throughout the brain and spinal cord of Ercc1D/-
of 16 weeks and older (Supplementary Fig. 1h and
Fig. 2d). This age-related increase of GFAP staining was
particularly evident in the molecular layer of cerebellar
cortex where the size and number of areas with intensely
GFAP-immunoreactive astrocytes correlated with increased
age, and loss of calbindin immunoreactivity which in cer-
ebellum represents a selective marker for Purkinje cells
(Supplementary Fig. 2).
To examine parallel changes in microglia, we stained for
the complement 3 receptor (CR3) present on all microglia
cells [5] and Mac2 (also known as galectin-3), a protein
that is expressed by activated phagocytosing microglia
[53]. Control brain and spinal cord show no or very low
levels of Mac2-positive microglial cells (Fig. 3a, c–e),
while CR3-positive microglia cells showed a quiescent
morphology (Supplementary Fig. 3a). In Ercc1D/- mice, a
low level of Mac2-positive microglia cells occurred
throughout the brain (not shown) and spinal cord (Fig. 3c,
f) at 4 weeks. At older age, Ercc1D/- mice showed an
increasing amount of clusters of Mac2-positive microglia
cells throughout the nervous system, but in particular in the
caudal brain stem and spinal cord (Fig. 3b, g). Within
the spinal cord, activated microglia were present both in
the gray and white matter, with relatively high levels in the
ventral horn, often in close proximity of motor neurons
(Supplementary Fig. 3). Taken together, these data indicate
that Ercc1D/- mice show age-dependent astrocytosis and
microglia cell activation, pointing to an increased occur-
rence of neuronal degeneration throughout the brain and
spinal cord.
Death of neurons and non-neuronal cells in the spinal
cord of Ercc1D/- mice
To obtain direct evidence for neuronal degeneration in the
spinal cord, we used a silver staining method that selec-
tively labels degenerating neurons and their processes
(Fig. 4). Ercc1D/- mice showed an age-related increase in
staining of argyrophilic processes and neuronal cell bodies
throughout the spinal cord, not observed in wild-type
controls (Fig. 4). Argyrophilic processes, mostly repre-
senting degenerating axons, were more frequent in the
white matter as compared to the gray matter, in particular
in the dorsal columns (Fig. 4c–e). In addition, infrequent
argyrophilic neuronal cell bodies were observed in the
motor columns of spinal cord from 8- and 16-week-old
Ercc1D/- mice (Fig. 4b). Analysis of 25 L4 sections of
16-week-old Ercc1D/- mice (n = 4), containing approxi-
mately 1,000 motor neurons, identified two argyrophilic
motor neurons, suggesting that approximately one in 500
motor neurons was in a moribund stage. The same fre-
quency of dying motor neurons was observed in spinal cord
sections stained for active caspase 3, a major proteolytic
protein in multiple cell death pathways (Supplementary
Fig. 4b). Active caspase 3 staining was also associated with
cells with a shrunken apoptotic morphology or with
irregular structures, putatively reflecting remnants of dead
cells (Supplementary Fig. 4). Apoptotic cells were also
identified in the white matter (Supplementary Fig. 4c, d),
indicating that glial cell death was likely to be occurring in
Ercc1D/- mice. Data from active caspase 3 staining were
confirmed by TUNEL staining for detecting DNA
Fig. 2 Age-related increase in
GFAP immunostaining in spinal
cord of Ercc1D/- mice.
Transverse lumbar L4 sections
stained for GFAP illustrating
mild increase in GFAP staining
in spinal cord of Ercc1D/- mice
at 4 weeks (b) and robust
increase at 16 weeks (d). df
dorsal funiculus, DH dorsal
horn, IZ intermediate zone,
VH ventral horn. Scale bar
500 lm (b)
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fragmentation [23], showing increased levels of TUNEL-
positive cells in spinal cord of Ercc1D/- mice (Supple-
mentary Fig. 4e–g). Taken together, these cell death
markers provide evidence for a low level of ongoing cell
death in Ercc1D/- spinal cord.
Loss of motor neurons, axonal pathology,
and neuromuscular denervation in Ercc1D/- mice
To directly examine the extent of motor neuron loss, we
counted motor neurons in serial sections immunostained
for choline acetyltransferase (ChAT), or CGRP, a peptide
expressed by a subpopulation of large motor neurons [64].
The numbers of both ChAT-labeled and CGRP-labeled
motor neurons were significantly reduced in 8- and 16-
week-old Ercc1D/- mice compared to 4-week-old Ercc1D/-
mice and age-matched wild-type controls (Fig. 5a–e). As
motor nerve terminals at the neuromuscular junction are
known to be early pathological targets in degenerating
lower motor neurons [40, 42], we analyzed neuromuscular
junction integrity in deep lumbrical muscles (Fig. 6). There
was widespread evidence of denervated muscle fibers
where pre-synaptic motor nerve terminals had degenerated,
entirely or partially vacating the post-synaptic motor end-
plate from Ercc1D/- mice at 8 and 16 weeks (Fig. 6). A
subset of motor endplates was innervated by more than one
incoming axon collateral (Fig. 6b). Quantification of neu-
romuscular morphology revealed a significant decrease in
normal neuromuscular junctions and corresponding
increases in the numbers of partially occupied, vacant and
poly-innervated neuromuscular junctions in Ercc1D/- mice
at 8 and 16 weeks (Fig. 6d–g).
Analysis of motor nerve terminals revealed signs of
neurofilament accumulation (Fig. 6a) as well as axon bleb-
bing in distal motor axons (Fig. 6c). Neurofilament
abnormalities also occurred in the proximal motor axons and
the cell body (not shown). The same changes were observed
with an antibody against peripherin (Fig. 5f–h), a type III
intermediate filament protein predominantly expressed in
axons of dorsal root ganglion cells and motor neurons that is
associated with cytoskeletal pathology in ALS and aging
motor neurons [67]. Hence, a subset of motor neurons
showed substantial increased peripherin immunoreactivity
in the cell body and the proximal axon coursing through the
ventral gray and white matter. Axons with increased neu-
rofilament and peripherin immunoreactivity showed an
Fig. 3 Mac2-positive
microgliosis in Ercc1D/- brain
and spinal cord. Parasagittal
brain (a, b) and transverse
lumbar L4 sections (d–g) of
Ercc1D/- and wt mice stained
for the phagocytosing microglia
marker Mac2 showing Mac2-
positive microglia throughout
Ercc1D/- brain and spinal cord
at 16 weeks (b, g). In the brain,
the highest levels of Mac2-
positive microglia occur in
caudal brain stem (arrow, b)
and white matter of cerebellar
cortex. In spinal cord, highest
levels of Mac2-positive
microglia occur in white matter
and motor columns in the
ventral horn (g). Mac2-positive
microglia cells are also present
in 4-week-old Ercc1D/- spinal
cord (arrow, f), but at much
lower levels than at 16 weeks.
c Values in bar graph are
mean ± SE of four mice based
on countings of three L4
sections per mouse. Hip
hippocampus, MeO medulla
oblongata, Mes mesencephalon,
NCx neocortex, Th thalamus.
Scale bars 2 mm (a) and
500 lm (d)
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expanded morphology (Fig. 5g, h) reminiscent of axonal
swellings such as those observed in ALS and aging spinal
cord [67]. The neurofilament and peripherin abnormalities
were already present at 4 weeks of age (not shown), and
were more frequent at 8 (Fig. 5g, h) and 16 weeks.
p53 and ATF3 activation in partially overlapping
populations of Ercc1D/- motor neurons
To further examine the link between motor neuron degen-
eration and DNA damage, we studied the expression of the
transcription factor p53, which is known to be activated by
multiple types of DNA damage and to mediate neuronal
degeneration [34]. P53-immunohistochemistry revealed
cells with intense nuclear p53-staining throughout Ercc1D/-
spinal cord, while no labeled cells occurred in wild-type or
Ercc1-/? spinal cords (Fig. 7a–c). Labeled cells were
present in the white and the gray matter, and occasionally
could be identified as motor neurons on the basis of local-
ization in the ventral horn and somatodendritic morphology
and size. Double labeling with the astrocytic marker GFAP,
the neuronal marker NeuN or the motor neuron marker
ChAT, respectively, confirmed that p53 labeling was pres-
ent in neurons and astrocytes (Fig. 7g–i), with the latter
accounting for most p53-positive cells in white matter. P53-
positive astrocytes and neurons were present in spinal cord
of 4-week-old Ercc1D/- mice, but were more frequent at 8
and 16 weeks (Fig. 7c).
To further explore the DNA damage response in neu-
rons in Ercc1D/- spinal cord, we studied the expression of
the stress-inducible transcription factor ATF3, which is
induced following genotoxic stress via p53-dependent and
-independent pathways [20, 25, 60]. ATF3, while mini-
mally expressed in control spinal cord, was clearly present
in an increasing amount of Ercc1D/- motor neurons as well
as other spinal cord neurons localized in the intermediate
zone and dorsal horn (Fig. 7d–f). Quantitative analysis of
L4 lumbar sections indicated that ATF3-positive motor
neurons were more frequent than p53-positive motor
neurons. Accordingly, double-labeling for p53 and ATF3
indicated that the majority of ATF3-positive motor neu-
rons (33 of 38) were p53-negative, while approximately
equal amounts of p53-positive motor neurons were ATF3-
negative (6 of 11) or ATF3-positive (5 of 11; Fig. 7j–l).
Fig. 4 Neuronal degeneration
in Ercc1D/- spinal cord. Silver
degeneration staining
visualizing the distribution of
neuronal degeneration in
Ercc1D/- spinal cord. Note an
argyrophylic motor neuron (b,
arrow) and an age-related
increase in the amount of
argyrophilic fibers in the dorsal
funiculus (c–e). Scale bars
250 lm (a), 50 lm (c)
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A variety of Golgi apparatus abnormalities in Ercc1D/-
motor neurons
Sections stained for CGRP, which in wild-type motor
neurons is predominantly localized in the Golgi apparatus
(Fig. 5a), revealed subcellular abnormalities suggestive of
an abnormal Golgi apparatus in a subset of Ercc1D/- motor
neurons (Fig. 5d). To systematically characterize Golgi
abnormalities, we performed double labeling of p53 or
ATF3 with an antibody against the cis-Golgi protein
GM130 [44]. This analysis showed that ATF3- and p53-
labeled motor neurons display a variability of abnormal
morphologies of the Golgi apparatus, consisting of frag-
mentation of Golgi stacks (Fig. 8c, d, f–h, l, m), or the
redistribution of unfragmented or fragmented Golgi stacks
to part of the cell body (Fig. 8b, i, k, l). In some motor
neurons, GM130 labeling was restricted to a very small
portion of the cell body, occasionally giving the impression
that GM130 labeling had entirely disappeared from the cell
(Fig. 8b, i, k). Double labeling of GM130 and CGRP
showed that in motor neurons with fragmented Golgi,
GM130 and CGRP maintain their adjoining, slightly over-
lapping localization (Fig. 8e, f) which points to
fragmentation into ministacks. Motor neurons with redis-
tribution of GM130 staining to a restricted area of the cell
body showed a similar redistribution of CGRP (Fig. 5d), but
in some occasions also showed a dramatic accumulation of
CGRP in the rest of the cell body (Fig. 5c), putatively
representing the accumulation of post-Golgi CGRP vesicles
[64]. The same was observed with an antibody against
SCG10 (Fig. 8i), a tubulin-binding protein that is associated
with the trans-Golgi and post-Golgi vesicles [13]. In con-
trast, no major changes were observed in the intracellular
distribution of endoplasmic reticulum proteins calreticulin
and VAPB [57], even in Ercc1D/- motor neurons with
considerably altered GM130 distribution (Fig. 8j, k).
Systematic analysis of 250 lumbar L4 motor neurons in
ATF3/GM130-stained sections from 16-week-old Ercc1D/-
Fig. 5 Motor neuron loss in Ercc1D/- spinal cord. a–d Low- (a, b)
and high-magnification (a0, b0, c, d) photomicrographs of CGRP
staining in the ventral horn of wt (a) and Ercc1D/- (b–d) spinal cord.
In control motor neurons, CGRP is predominantly localized to a
network of linear profiles representing the Golgi apparatus. Note a
variety of abnormalities of CGRP distribution in a subset of Ercc1D/-
motor neurons, including diffuse punctate staining in the cell body
(b0), axonal accumulation of CGRP (arrow, c), and redistribution of
the labeling to part of the cell body (d). e Bar graphs showing the
number of CGRP and choline acetyltransferase (ChAT)-labeled motor
neurons in L4 spinal cord sections of wt and Ercc1D/- mice. Values
are mean ± SE of four mice, while value per mouse is the mean of
six L4 sections. Note age-related decrease of the number of motor
neurons in Ercc1D/- mice. *,**,***P \ 0.05, 0.01, and 0.001
compared to wt mice of the same age (one-way ANOVA with
Tukey’s multiple comparison test); #P = 0.002 (post-test for linear
trend). f–h Photomicrographs of peripherin immunostaining in the
ventral horn of wt (f) and Ercc1D/- (g, h) spinal cord, showing
increased peripherin immunostaining in a subset of motor neurons and
motor axons (arrows, g). Scale bars 100 lm (a) and 25 lm (c, d, h)
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mice (n = 3) indicated that at this age as many as 25% (63
of 250) of motor neurons had an abnormal Golgi mor-
phology, 22% (14 of 63) of which showed Golgi
fragmentation. This analysis also showed that all ATF3-
positive Ercc1D/- motor neurons had an abnormal Golgi
with various morphologies (Fig. 8b, c). Inversely, only a
minority (21 of 63) of motor neurons with an abnormal
Golgi was positive for ATF3 (Fig. 8d). Similarly, analysis
of p53/GM130-stained sections showed that the majority
(36 of 42) of motor neurons with Golgi abnormalities were
p53-negative. Inversely, all p53-positive motor neurons (6
of 6) in this analysis had an abnormal Golgi apparatus
(Fig. 8g, h). These data indicate that Golgi abnormalities
represent a sensitive marker for cellular deficits in motor
neurons.
To determine the extent to which p53- and ATF3-posi-
tive Ercc1D/- motor neurons and motor neurons with
abnormal GM130 labeling were towards the final stages of
cell death, we double-labeled for Mac2 outlining phago-
cytosing microglia (see above). This analysis revealed a
Fig. 6 Synaptic pathology at the neuromuscular junction in Ercc1D/-
mice. a–c Confocal micrographs of neuromuscular junctions from
lumbrical muscles of 16-week-old Ercc1D/- mice labeled with
rhodamine a-bungarotoxin to reveal post-synaptic motor endplates
(red) and antibodies against 150 kDa neurofilaments to reveal pre-
synaptic axons and motor nerve terminals (green). Examples of
‘normal’ (white arrows), denervated (pink arrow, a), partially
denervated (pink arrowhead, a), poly-innervated (cyan arrows, b),
and neuromuscular junctions are shown. Examples of motor nerve
terminals with conspicuous neurofilament accumulation are indicated
by the white arrowheads in a. Also note the presence of axon
blebbing in c where the incoming axon is very thin (yellow arrow),
but is interspersed by regions of neurofilament accumulations (yellow
arrowhead). d–g Quantification of synaptic pathology in 4–16-week-
old Ercc1D/- mice compared to wild-type controls. *,**,***P \ 0.05,
0.01, and 0.001, respectively, compared to wt mice of the same age
(Kruskal–Wallis test with Dunn’s post-hoc test). Scale bars 40 lm (a,
b) and 20 lm (c)
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small subset (\10%) of afflicted Ercc1D/- motor neurons
surrounded by phagocytosing microglia (Supplementary
Fig. 5). Taken together, our pathological analyses indicate
that Ercc1D/- motor neurons may experience a variability
of cellular deficits that ultimately lead to cell death.
Motor neurons of Ercc1D/- mice do not show TDP-43
or FUS abnormalities
Finally, we examined the extent to which the neurode-
generative phenotype observed in Ercc1D/- motor neurons
Fig. 7 Genotoxic stress-responsive transcription factor p53 and
ATF3 expression in Ercc1D/- spinal cord. a–f Photomicrographs (a,
b, d, e) and bar graphs (c, f) of p53 (a–c) and ATF3 (d–f)
immunostaining, illustrating induction of p53 (arrows; b, b0) and
ATF3 (arrow, e0) expression in Ercc1D/- motor neurons. Prominent
p53 labeling also occurred in astrocytes (arrowhead, b), while both
p53 and ATF3 were expressed by interneurons in the spinal cord
intermediate zone and dorsal horn (c, f). Values in c and f are
mean ± SE of four mice, while value per mouse is from ten L4
sections. g–i Double-labeling confocal images showing p53–NeuN (g,
h) and p53–GFAP (i) double-labeled cells in Ercc1D/- spinal cord. j–l
Double-labeling confocal immunofluorescence of p53 and ATF3
showing that p53 and ATF3 in most instances are expressed in
distinct cells in Ercc1D/- spinal cord sections. ATF3 single-labeled
motor neurons (small arrows; j, k) occurred more frequently than p53
single-labeled motor neurons (large arrows; j, k) and double-labeled
cells (arrowhead; j, l). Scale bars 100 lm (d, j), 25 lm (g, h) and
10 lm (i, l)
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has features in common with ALS by staining for nuclear
TAR-DNA-binding protein-43 (TDP-43), a DNA/RNA-
binding protein whose accumulation in the cytoplasm and
subsequent aggregation into inclusions represents a key
pathological feature in the majority of ALS cases [46], and
FUS protein, another DNA/RNA-binding protein that mi-
slocalizes to the cytoplasm and aggregates in a familial
form of ALS [31]. Screening of more than 50 spinal cord
sections from six 16–20-week-old Ercc1D/- mice indicated
that all cells, including motor neurons with abnormal Golgi
apparatus and nuclear morphology, showed normal nuclear
TDP-43 and FUS staining (Fig. 8l, m). Accordingly,
immunostaining with an anti-ubiquitin antibody did not
reveal any cells with ubiquitinated pathological protein
inclusions, a feature associated with TDP43 pathology in
ALS [46].
Discussion
In this study, we provide direct evidence that modifications
in DNA repair pathways are a robust modulator of motor
neuron vulnerability in vivo. We show that Ercc1D/- mice
develop an age-dependent degeneration of motor neurons
and progressive loss of neuromuscular connectivity. Motor
neuron degeneration occurred in parallel with signs of
astrocyte and microglia activation, and was associated with
several morphological and molecular changes, including
Fig. 8 Golgi apparatus abnormalities in Ercc1D/- motor neurons.
Double-labeling confocal immunofluorescence of the cis-Golgi
protein GM130 with ATF3 (a–d), CGRP (e, f), p53 (g, h), SCG10
(i), VAPB (j, k), TDP43 (l), or FUS (m) in motor neurons of wt (a, e,
j) and Ercc1D/- (b–d, f–i, k–m) spinal cord. A variety of Golgi
abnormalities occur in Ercc1D/- spinal cord, including a redistribution
of GM130 staining to a small part of the cell (b, i, k, l) and
fragmentation (c, d, f–h, l, m). Golgi abnormalities may (b, c) or may
not (arrowhead, d) be associated with ATF3 expression. Motor
neurons that are positive for p53 generally display Golgi fragmen-
tation (g, h). In motor neurons with fragmented Golgi, GM130 and
CGRP, which are localized in the cis- and trans-Golgi, respectively,
maintain their adjoining slightly overlapping localization (e, f). Motor
neurons with redistributed Golgi apparatus show normal distribution
of endoplasmic reticulum-associated protein VAPB (k). Motor
neurons with severely abnormal Golgi apparatus morphologies show
a normal nuclear distribution of TDP43 and FUS (l, m). Scale bars
50 lm (a), 20 lm (c, d, i) and 10 lm (e–m)
Acta Neuropathol (2010) 120:461–475 471
123
neurofilament and peripherin abnormalities in the cell body
and the axon, misplaced and flattened nuclei, morphological
changes of the Golgi apparatus, and expression of the
transcription factors p53 and ATF3. Neurofilament accu-
mulations in distal axons and motor nerve terminals are a
well-documented feature of motor neuron pathology in
many different animal models of motor neuron degenera-
tion, thought to occur due to disrupted cytoskeletal
organization and impaired axonal transport [40, 69]. P53
and ATF3, which are both known to be activated in
response to genotoxic stress [20, 34, 68], were expressed in
largely non-overlapping populations of motor neurons. This
differential expression of stress genes in different motor
neurons may be explained by heterogeneity of cellular
damage responses triggered by different cellular deficits. A
heterogeneity of cellular deficits was also suggested by the
Golgi apparatus abnormalities, occurring in a large pro-
portion of motor neurons on many occasions in the absence
of ATF3 or p53 expression, and being variable as compared
to the relatively stereotyped Golgi abnormalities known to
occur in other neurodegenerative conditions targeting motor
neurons, such as ALS [24, 64]. The Golgi apparatus is a
highly dynamic organelle whose morphology depends on a
large variety of protein components and cellular processes,
and alters under a wide variety of conditions, including
impaired endoplasmic reticulum function, disruption of the
trafficking and sorting machinery, altered lipid metabolism,
and activation of cell death pathways [4, 16, 24, 48, 58].
Thus, the large number of factors influencing the mor-
phology and function of the Golgi apparatus may render it
relatively vulnerable to stochastic DNA damage afflicting
the transcription of randomly distributed genes, and might
explain the high frequency and heterogeneity of Golgi
abnormalities in Ercc1D/- motor neurons. Taken together
our pathological data are compatible with a model where
motor neurons in Ercc1D/- mice are afflicted by stochastic
DNA lesions that block or deregulate gene expression, and
indicate that motor neurons require efficient ERCC1-
dependent DNA repair pathways for long-term survival.
Our data complement previous observations in ERCC1
and XPF-deficient patients [29, 49] and in Ercc1-/- and
Xpf-/- mice [33, 38, 49, 59, 65] indicating that loss of
ERCC1/XPF nuclease function causes a progeroid degen-
erative phenotype in several organ systems and juvenile
death. Ercc1-/- mice have also been reported to develop
motor problems [38, 49, 65], which were assigned to
developmental and degenerative abnormalities of the cere-
bellar cortex [29]. The short life span of Ercc1-/- mice used
in these studies precluded the systematic investigation of
age-dependent neurodegenerative changes. We did not
observe obvious structural abnormalities in the nervous
systems of our Ercc1D/- mice at 4 weeks of age, apart from
reduced size and some initial signs of neuronal degeneration.
Although at this point subtle neurodevelopmental changes
cannot be ruled out, the lack of a neurodevelopmental phe-
notype such as observed in Ercc1-/- mice can be explained
by the low level of residual ERCC1/XPF activity in Ercc1D/-
mice [50, 65]. Importantly, our data show that the progres-
sion of motor abnormalities in Ercc1D/- mice correlated with
the time course of neurodegenerative changes, indicating
that the motor deficits observed may occur as a result of
degenerative changes in the neuromuscular system. As
Ercc1D/- mice also develop age-related degenerative chan-
ges throughout the rest of the brain, also deficits in other
motor areas, including the sensorimotor cortex and the cer-
ebellum may contribute to the progressive motor deficits.
The identity of the DNA lesions triggering neurode-
generative changes in Ercc1D/- mice remains to be
determined. Oxidative base damage such as 7,8-dihydro-8-
oxoguanine (8-oxoG) is repaired by the base excision
repair (BER) pathway and may not accumulate in Ercc1D/-
mice. However, other oxidative lesions such as malondi-
aldehyde adducts and 8,50-cyclopurine-20-deoxynucleotides
are both NER substrates and potential threats to tran-
scription [11, 22, 51]. The involvement of ERCC1/XPF as
a nuclease in multiple repair pathways in addition to NER
(interstrand crosslink repair and DSB repair) raises the
question whether the neurodegenerative changes observed
were caused by deficiency in one of these pathways, or by
synergistic deleterious actions resulting from defects in
multiple pathways [26, 65]. Patients with XPA-mutations
that are selectively deficient in NER develop juvenile or
adult onset of neuronal degeneration which indicates that
NER deficiency alone can cause neuronal degeneration [7,
30]. However, Xpa-/- mice that are entirely NER deficient
have not been reported to develop noticeable neurological
or neurodegenerative abnormalities up to 2 years of age
[39, 45], and accordingly, extensive analyses of Xpa-/-
spinal cords revealed very infrequent p53-positive cells
(\1 per mm2; Jaarsma, unpublished observation). Instead,
the Xpa-/- genotype causes a severe progeroid phenotype
when crossed into mice that are deficient in transcription
coupled repair [6, 62], indicating that NER deficiency may
exacerbate the deleterious effects of deficiencies in other
repair pathways [26]. Accordingly, the degenerative
changes in motor neurons that we observed here may result
from combined deficiencies in NER and other repair
pathways depending on ERCC1/XPF.
Cumulative DNA damage and abnormalities in DNA
repair pathways have been implicated in ALS and other
motor neuron diseases, but genetic evidence pointing to
DNA repair genes as a risk or causative factor is inconclusive
or lacking [15, 36]. A potential exception is provided by
mutations in SETX that are linked to a rare dominant slowly
progressing early onset motor neuron disease (ALS4) [14].
SETX is a DNA/RNA helicase that has been implicated in
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the defense against oxidative DNA damage [56]. The ALS4
mutation of SETX may lead to the dysfunction of its helicase
activity [14], but how this is connected to motor neuron
degeneration and whether it involves DNA damage is not
understood. Other evidence involving DNA damage in
motor neuron disease comes from pathological studies,
suggesting increased levels of DNA lesions and p53 acti-
vation in post-mortem ALS motor neurons, but these
changes are thought to represent late events rather than
causative factors in the degenerative cascade [36]. In the
present study, we show that Ercc1D/- motor neurons do not
develop TDP43 pathology which is a key pathological fea-
ture in the majority of ALS patients [46], a minority of which
have mutations in the TDP43 gene, while the majority being
caused by mechanisms that remain to be defined [31, 47].
This indicates that DNA damage resulting from ERCC1
deficiency is not sufficient to trigger the events yielding ALS
pathology. Rather we propose that cumulative DNA damage
may act as one of the age-related risk factors contributing to
degenerative disorders such as ALS.
In summary, we propose that DNA repair pathways may
have a hitherto unappreciated role in neuromuscular form
and function in human neurodegenerative disease, and that
the Ercc1D/- mouse provides an excellent model to study
the effects of accelerated aging on the neuromuscular
system in vivo. In addition, the Ercc1D/- mice may rep-
resent a unique mouse model for testing interventional
approaches aimed at reducing genotoxic stress in neurons.
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